Type IIID Congenital Disorder Of Glycosylation

mutation of B4GALT1

Also Known As:

Congenital Disorder Of Glycosylation, Type IIID; CDG IID; CDG2D; CDGIID

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders)
2.	Muscular Diseases (Myopathy)
3.	Hydrocephalus (Hydrocephaly)

Drugs and Important Biological Agents (IBA) related to Type IIID Congenital Disorder Of Glycosylation:

1.	Uridine Diphosphate (UDP)IBA 03/01/2002 - "Deficiency of the Golgi enzyme UDP-Gal:N-acetylglucosamine beta-1,4-galactosyltransferase I (beta4GalT I) (E.C.2.4.1.38) causes a new congenital disorder of glycosylation (CDG), designated type IId (CDG-IId), a severe neurologic disease characterized by a hydrocephalus, myopathy, and blood-clotting defects. "
2.	EnzymesIBA 03/01/2002 - "Deficiency of the Golgi enzyme UDP-Gal:N-acetylglucosamine beta-1,4-galactosyltransferase I (beta4GalT I) (E.C.2.4.1.38) causes a new congenital disorder of glycosylation (CDG), designated type IId (CDG-IId), a severe neurologic disease characterized by a hydrocephalus, myopathy, and blood-clotting defects. "
3.	AcetylglucosamineIBA 03/01/2002 - "Deficiency of the Golgi enzyme UDP-Gal:N-acetylglucosamine beta-1,4-galactosyltransferase I (beta4GalT I) (E.C.2.4.1.38) causes a new congenital disorder of glycosylation (CDG), designated type IId (CDG-IId), a severe neurologic disease characterized by a hydrocephalus, myopathy, and blood-clotting defects. "
4.	beta-1,4-galactosyltransferase IIBA 03/01/2002 - "Deficiency of the Golgi enzyme UDP-Gal:N-acetylglucosamine beta-1,4-galactosyltransferase I (beta4GalT I) (E.C.2.4.1.38) causes a new congenital disorder of glycosylation (CDG), designated type IId (CDG-IId), a severe neurologic disease characterized by a hydrocephalus, myopathy, and blood-clotting defects. "